What treatment did Kyle Planck receive for monkeypox?

Question

Accepted Answer

Kyle Planck Received TPOXX Treatment for Monkeypox

Kyle Planck, a 26-year-old New Yorker, received treatment with TPOXX, also known as Tecovirimat, for his monkeypox infection. TPOXX is an antiviral medication originally developed for human smallpox, which was authorised for use in a trial against monkeypox. Planck was able to begin this treatment on July 6, the day after he was tested for the virus.
Antiviral Drug TPOXX Used in Trial

TPOXX, or Tecovirimat, is an antiviral drug that has been authorised for use in trials targeting monkeypox. While originally developed to combat human smallpox, its efficacy against the monkeypox virus has led to its inclusion in treatment protocols for affected individuals. Planck's case highlights the availability of this specific antiviral for those who can access trial participation.
Planck's Experience with Symptoms and Treatment

Planck experienced severe symptoms, including a fever and approximately 30 lesions that spread across his body. The pain, particularly from lesions on his mucus membranes, was described as the worst he had ever experienced, leading him to take frequent warm baths. He began treatment with TPOXX on July 6, following his positive test for monkeypox on July 5.
Access to Treatment and Medical Community Proximity

Planck acknowledged that his connection to the medical community facilitated his enrollment in the study for TPOXX treatment. He recognised that this access is not a reality for most individuals in New York, describing the situation as unfortunate. This suggests a potential disparity in accessing experimental treatments for the virus.

Reading history

Hide →

This history is cleared when the page is closed.

What treatment did Kyle Planck receive for monkeypox?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends